Therapies

Our dedication
to R&D

Therapies
Kedrion Biopharma’s line of plasma-derived therapies is broad and diverse. With products to treat or prevent many rare diseases and conditions from hemolytic disease of the fetus and newborn to immune deficiencies to hemophilia, Kedrion Biopharma offers a wide and expanding array of treatments and therapies. (Update April 2025)
Therapeutic areas
Browse areas and view all products related to
Select area
Rare and ultra-rare diseases / Coagulation disorders
Immunology / Neurology
Critical care
Mother and child health

Rare and ultra-rare diseases / Coagulation disorders

Ryplazim

Plasma-derived human
Plasminogen

View product website

Coagadex

Human coagulation
Factor X

View product website

Koāte

Human coagulation
Factor VIII

View product website

Immunology / Neurology

GAMMAPLEX

Human normal i.v. Immunoglobulin 5% and 10%

View product website

GAMMAKED

Human normal i.v. Immunoglobulin 10%

View product website

Critical care

KEDBUMIN

Human Albumin solution

View product website

Albuked

Human Albumin solution

View product website

albuminex

Human Albumin solution

View product website

KEDRAB

Human Rabies Immunoglobulin

View product website

Mother and child health

RhoGAM

Human Anti D Immunoglobulin

View product website
NEWS

Discover our press releases, resources, events and stay updated on the latest news

Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients 21-03-2025 Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients Read the news
FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim® 20-11-2024 FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim® Read the news
Kedrion and Biotest Finalize Yimmugo Commercialization for US 02-10-2024 Kedrion and Biotest Finalize Yimmugo Commercialization for US Read the news